These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 28749092)

  • 1. Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency?
    Andrade C
    J Clin Psychiatry; 2017 Jul; 78(7):e852-e857. PubMed ID: 28749092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Ketamine for Depression, 2: Practical Considerations.
    Andrade C
    J Clin Psychiatry; 2019 Apr; 80(2):. PubMed ID: 30997961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression.
    Loo CK; Gálvez V; O'Keefe E; Mitchell PB; Hadzi-Pavlovic D; Leyden J; Harper S; Somogyi AA; Lai R; Weickert CS; Glue P
    Acta Psychiatr Scand; 2016 Jul; 134(1):48-56. PubMed ID: 27028832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Ketamine for Depression, 1: Pharmacologic Considerations and Clinical Evidence.
    Andrade C
    J Clin Psychiatry; 2019 Apr; 80(2):. PubMed ID: 30946543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of route of administration on the enantioselective pharmacokinetics of ketamine and norketamine in rats.
    Le Nedelec M; Glue P; Winter H; Goulton C; Medlicott NJ
    J Psychopharmacol; 2018 Oct; 32(10):1127-1132. PubMed ID: 29895202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.
    Cusin C; Ionescu DF; Pavone KJ; Akeju O; Cassano P; Taylor N; Eikermann M; Durham K; Swee MB; Chang T; Dording C; Soskin D; Kelley J; Mischoulon D; Brown EN; Fava M
    Aust N Z J Psychiatry; 2017 Jan; 51(1):55-64. PubMed ID: 26893373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketamine for the treatment of depression.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2013 Jan; 51(1):11-4. PubMed ID: 23413455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action.
    Andrade C
    J Clin Psychiatry; 2017 Apr; 78(4):e415-e419. PubMed ID: 28448702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression.
    Szymkowicz SM; Finnegan N; Dale RM
    J Affect Disord; 2013 May; 147(1-3):416-20. PubMed ID: 23182590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Ketamine for Depression: A Systematic Review.
    Rosenblat JD; Carvalho AF; Li M; Lee Y; Subramanieapillai M; McIntyre RS
    J Clin Psychiatry; 2019 Apr; 80(3):. PubMed ID: 30995364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study.
    Hartberg J; Garrett-Walcott S; De Gioannis A
    Psychopharmacology (Berl); 2018 Feb; 235(2):393-398. PubMed ID: 29151192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions.
    Riva-Posse P; Reiff CM; Edwards JA; Job GP; Galendez GC; Garlow SJ; Saah TC; Dunlop BW; McDonald WM
    J Affect Disord; 2018 Aug; 236():291-297. PubMed ID: 29525051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of subcutaneous esketamine on blood pressure and heart rate in treatment-resistant depression.
    Del Sant LC; Sarin LM; Magalhães EJM; Lucchese AC; Tuena MA; Nakahira C; Fava VAR; Delfino R; Surjan J; Steiglich MS; Barbosa M; Abdo G; Cohrs FM; Liberatori A; Del Porto JA; Lacerda ALT; de Jesus Mari J
    J Psychopharmacol; 2020 Oct; 34(10):1155-1162. PubMed ID: 32638662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated ketamine injections in synergy with antidepressants for treating refractory depression: A case showing 6-month improvement.
    Wang M; Xiong Z; Su B; Wang L; Li Z; Yang Y; Fang J; Li Z
    J Clin Pharm Ther; 2020 Feb; 45(1):199-203. PubMed ID: 31468568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic Syndrome Rather Than Body Mass Index Is Associated With Treatment Response to Ketamine Infusions.
    Dale RM; Bryant KA; Thompson NR
    J Clin Psychopharmacol; 2020; 40(1):75-79. PubMed ID: 31834094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
    Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
    Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression.
    Lara DR; Bisol LW; Munari LR
    Int J Neuropsychopharmacol; 2013 Oct; 16(9):2111-7. PubMed ID: 23683309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ketamine as a new treatment for depression: a review of its efficacy and adverse effects.
    Katalinic N; Lai R; Somogyi A; Mitchell PB; Glue P; Loo CK
    Aust N Z J Psychiatry; 2013 Aug; 47(8):710-27. PubMed ID: 23661785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression.
    Liebrenz M; Stohler R; Borgeat A
    World J Biol Psychiatry; 2009; 10(4 Pt 2):640-3. PubMed ID: 17853274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.